Summary

Global Branded Generics Market is valued at approximately USD 432.30 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 14.66% over the forecast period 2024-2032. Branded generics are medications bioequivalent to original innovator drugs and are marketed under a different brand name by another company post-patent expiration. These drugs, formulated using the same active pharmaceutical ingredients (APIs) as the innovator product, must meet similar regulatory requirements for manufacturing, safety, and efficacy standards. The primary growth drivers for the branded generics market include rising consumer awareness of accessible treatment options, increasing healthcare expenditure, and numerous patent expirations on blockbuster drugs.
Furthermore, the significant adoption of value-added branded generics, due to their additional benefits such as combined multiple active ingredients or innovative dosage forms, is driving market growth. For example, Benitek A (Olmesatran in combination with Amlodipine), Nifedical (nifedipine), and Digitek (digoxin) are some value-added products designed to enhance therapeutic effects or reduce side effects. However, the market faces challenges such as stringent regulatory requirements for drug approval and quality control, as well as price erosion due to intense competition among manufacturers.
The route of administration plays a crucial role in the market dynamics, with oral administration being the most common and preferred method due to its convenience and non-invasive nature. Parenteral and topical routes are also significant, particularly for drugs that require quick relief or localized delivery. The indication segment reveals a burgeoning utilization of branded generics for gastrointestinal and neurological diseases, with increasing demand for cost-effective therapies in these areas.
The key regions considered for the global Branded Generics Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Branded Generics Market in terms of revenue. The market growth in the region is being attributed to factors including robust healthcare infrastructure and high per capita spending on pharmaceuticals. Also, increasing healthcare expenditure and favorable pricing policies drive market demand. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by rising R&D activities, supportive government initiatives, and increasing demand for trade generics.
Major market players included in this report are:
Abbott Laboratories
Ajanta Pharma Ltd.
Alkem Laboratories Ltd.
Amneal Pharmaceuticals LLC
Apotex Inc.
Aspen Pharmacare Holdings Limited
AstraZeneca PLC
Aurobindo Pharma Limited
Bausch Health Companies Inc.
Bristol-Myers Squibb Company
Cipla Limited
Dr. Reddy’s Laboratories Ltd.
Endo International PLC
Eris Lifesciences Limited
Fresenius Kabi AG
The detailed segments and sub-segment of the market are explained below:
By Product:
• Trade Named Generics
• Value-Added
By Drug Type:
• Alkylating Agents
• Anti-depressants
• Anti-epileptics
• Anti-hypertensive
• Anti-psychotics
• Antimetabolites
• Hormones
• Lipid Lowering Drugs
By Route of Administration:
• Oral
• Parenteral
• Topical
By Indication:
• Acute & Chronic Pain
• Cardiovascular Diseases
• Dermatological Diseases
• Gastrointestinal Diseases
• Neurological Diseases
• Oncology
By Distribution Channel:
• Offline
• Online
By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
Latin America
• Brazil
• Mexico
• RoLA
Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA
Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Chapter 1. Global Branded Generics Market Executive Summary
1.1. Global Branded Generics Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Product
1.3.2. By Drug Type
1.3.3. By Route of Administration
1.3.4. By Indication
1.3.5. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Branded Generics Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Branded Generics Market Dynamics
3.1. Market Drivers
3.1.1. Increasing Consumer Awareness
3.1.2. Rising Healthcare Expenditure
3.1.3. Increasing Patent Expirations
3.2. Market Challenges
3.2.1. Stringent Regulatory Requirements
3.2.2. Price Erosion Due to Competition
3.3. Market Opportunities
3.3.1. Advancements in Pharmaceutical Research
3.3.2. Development of Bioequivalent Products

Chapter 4. Global Branded Generics Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Branded Generics Market Size & Forecasts by Product (2022-2032)
5.1. Segment Dashboard
5.2. Global Branded Generics Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Trade Named Generics
5.2.2. Value-Added

Chapter 6. Global Branded Generics Market Size & Forecasts by Drug Type (2022-2032)
6.1. Segment Dashboard
6.2. Global Branded Generics Market: Drug Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Alkylating Agents
6.2.2. Anti-depressants
6.2.3. Anti-epileptics
6.2.4. Anti-hypertensive
6.2.5. Anti-psychotics
6.2.6. Antimetabolites
6.2.7. Hormones
6.2.8. Lipid Lowering Drugs

Chapter 7. Global Branded Generics Market Size & Forecasts by Route of Administration (2022-2032)
7.1. Segment Dashboard
7.2. Global Branded Generics Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Oral
7.2.2. Parenteral
7.2.3. Topical

Chapter 8. Global Branded Generics Market Size & Forecasts by Indication (2022-2032)
8.1. Segment Dashboard
8.2. Global Branded Generics Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Acute & Chronic Pain
8.2.2. Cardiovascular Diseases
8.2.3. Dermatological Diseases
8.2.4. Gastrointestinal Diseases
8.2.5. Neurological Diseases
8.2.6. Oncology

Chapter 9. Global Branded Generics Market Size & Forecasts by Distribution Channel (2022-2032)
9.1. Segment Dashboard
9.2. Global Branded Generics Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
9.2.1. Offline
9.2.2. Online

Chapter 10. Global Branded Generics Market Size & Forecasts by Region (2022-2032)
10.1. North America Branded Generics Market
10.1.1. U.S. Branded Generics Market
10.1.1.1. Product breakdown size & forecasts, 2022-2032
10.1.1.2. Drug Type breakdown size & forecasts, 2022-2032
10.1.1.3. Route of Administration breakdown size & forecasts, 2022-2032
10.1.1.4. Indication breakdown size & forecasts, 2022-2032
10.1.1.5. Distribution Channel breakdown size & forecasts, 2022-2032
10.1.2. Canada Branded Generics Market
10.2. Europe Branded Generics Market
10.2.1. U.K. Branded Generics Market
10.2.2. Germany Branded Generics Market
10.2.3. France Branded Generics Market
10.2.4. Spain Branded Generics Market
10.2.5. Italy Branded Generics Market
10.2.6. Rest of Europe Branded Generics Market

10.3. Asia-Pacific Branded Generics Market
10.3.1. China Branded Generics Market
10.3.2. India Branded Generics Market
10.3.3. Japan Branded Generics Market
10.3.4. Australia Branded Generics Market
10.3.5. South Korea Branded Generics Market
10.3.6. Rest of Asia-Pacific Branded Generics Market

10.4. Latin America Branded Generics Market
10.4.1. Brazil Branded Generics Market
10.4.2. Mexico Branded Generics Market
10.4.3. Rest of Latin America Branded Generics Market

10.5. Middle East & Africa Branded Generics Market
10.5.1. Saudi Arabia Branded Generics Market
10.5.2. South Africa Branded Generics Market
10.5.3. Rest of Middle East & Africa Branded Generics Market

Chapter 11. Competitive Intelligence
11.1. Key Company SWOT Analysis
11.1.1. Company 1
11.1.2. Company 2
11.1.3. Company 3
11.2. Top Market Strategies
11.3. Company Profiles
11.3.1. Abbott Laboratories
11.3.1.1. Key Information
11.3.1.2. Overview
11.3.1.3. Financial (Subject to Data Availability)
11.3.1.4. Product Summary
11.3.1.5. Market Strategies
11.3.2. Ajanta Pharma Ltd.
11.3.3. Alkem Laboratories Ltd.
11.3.4. Amneal Pharmaceuticals LLC
11.3.5. Apotex Inc.
11.3.6. Aspen Pharmacare Holdings Limited
11.3.7. AstraZeneca PLC
11.3.8. Aurobindo Pharma Limited
11.3.9. Bausch Health Companies Inc.
11.3.10. Bristol-Myers Squibb Company
11.3.11. Cipla Limited
11.3.12. Dr. Reddy’s Laboratories Ltd.
11.3.13. Endo International PLC
11.3.14. Eris Lifesciences Limited
11.3.15. Fresenius Kabi AG

Chapter 12. Research Process
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes